Clinical Trial Detail

NCT ID NCT02265341
Title Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Mayo Clinic
Indications

biliary tract cancer

Therapies

Ponatinib

Age Groups: adult

Additional content available in CKB BOOST